Freespira: A Digital Therapeutic Gains Reimbursement for an Expensive Condition


Palo Alto Health Sciences has a digital therapeutic without a drug component. Once it surmounted the challenge of FDA clearance, if faced perhaps a bigger hurdle: reimbursement. The company did a study focused on the economic benefits of its solution, and gained reimbursement from one of the largest Blue Cross Blue Shield-affiliated insurers.

Maybe it’s because Palo Alto Health Sciences Inc. was in the right place at the right time, or perhaps it just picked the right claim for encouraging market adoption, but the company’s Freespira therapy for certain anxiety disorders is the rare non-drug digital therapy with reimbursement from a major commercial health insurer.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: